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The Genetic Association Information Network (GAIN) Data Access Committee was established in June 2007 to provide prompt and fair
access to data from six genome-wide association studies through the database of Genotypes and Phenotypes (dbGaP). Of 945 project
requests received through 2011, 749 (79%) have been approved; median receipt-to-approval time decreased from 14 days in 2007 to
8 days in 2011. Over half (54%) of the proposed research uses were for GAIN-specific phenotypes; other uses were for method develop-
ment (26%) and adding controls to other studies (17%). Eight data-management incidents, defined as compromises of any of the data-
use conditions, occurred among nine approved users; most were procedural violations, and none violated participant confidentiality.
Over 5 years of experience with GAIN data access has demonstrated substantial use of GAIN data by investigators from academic,
nonprofit, and for-profit institutions with relatively few and contained policy violations. The availability of GAIN data has allowed
for advances in both the understanding of the genetic underpinnings of mental-health disorders, diabetes, and psoriasis and the devel-
opment and refinement of statistical methods for identifying genetic and environmental factors related to complex common diseases.Genome-wide association studies
(GWASs), a proven strategy for identi-
fying common genetic variants associ-
ated with health and disease, produce
vast amounts of data suitable for
addressing a multitude of research
questions. The Genetic Association
Information Network (GAIN) was
established in 2006 to investigate
the genetic basis of common disease
by the creation of a network of six
collaborative GWASs in attention-
deficit hyperactivity disorder (MIM
143465]), bipolar disorder (MIM
125480), diabetic nephropathy in
type I diabetes (MIM 222100), major
depression (MIM 608516), psoriasis
(MIM 177900), and schizophrenia
(MIM 181500).1 GAIN’s driving
principle is that maximum public
benefit can be achieved if innovative
research is pursued through rich and
readily accessible genomic data in a
manner that promotes the utmost
respect and protection for research-1Division of Genomic Medicine, National Human G
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the contributions of the investigators
who submit data for broad sharing.2
Therefore, researchers can access
GAIN GWAS data through the
database of Genotypes and Pheno-
types (dbGaP),3 developed by the
National Center for Biotechnology
Information (NCBI). dbGaP provides
two levels of access—open and
controlled—to GAIN data. The open-
access (public) website provides
broad release of nonsensitive data
(e.g., study overviews and original
study protocols). The controlled-
access website provides individual-
level phenotypic and genotypic data
for GAIN GWASs, but only after a
researcher is approved to access the
data by the GAIN Data Access
Committee (DAC). GAIN has been at
the leading edge of implementation
of dbGaP’s controlled-access data-
request system and has served as a
precursor to the National Institutesenome Research Institute, National Institutes of He
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sharing model.
There aremany potential benefits of
wide-spread data sharing, and these
include opportunities to (1) replicate
GWAS findings in large data sets, (2)
develop and test statistical methods
for GWASs and other genomics
research, and (3) maximize the use
of GWAS data for the discovery of
health-related genetic variants and
their translation into effective thera-
peutic strategies. However, many
concerns were raised about this new
data-sharing model and its potential
risks to study participants and investi-
gators, as summarized in the preamble
to the NIH policy for sharing GWAS
data (GWAS policy). The concerns
included (1) the potential for nonre-
search uses of the data (e.g., by law-
enforcement agencies, employers, or
insurance companies) or for purposes
beyond the permitted scope of
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of data quality control and oversight
of data-submission and -access proce-
dures, (3) potential risks to participant
privacy, and (4) difficulties in enforc-
ing compliance with publication and
privacy policies. Although studies
have shown that participants gener-
ally support broad data sharing of
their individual-level genotype and
phenotype data,4 they also expect to
be asked whether their data can be
included in controlled-access data-
bases such as dbGaP.5 A recent
commentary called for greater trans-
parency with regard to the nature
and extent of dbGaP data sharing for
enhancing the trustworthiness of the
resource for data submitters and their
institutions.6
GAIN data have been available
through dbGaP for over 5 years, and
nearly 1,000 project requests (PRs)
have been received and reviewed by
the GAIN DAC. Here, we hope to
provide greater transparency of the
GAIN controlled-access data-sharing
model by describing (1) the GAIN
data sets and their data-use limita-
tions (DULs), (2) the function of the
GAIN DAC and key aspects of its
governance, (3) the number and
type of PRs for GAIN data sets, and
(4) the limitations and strengths
of this new controlled-access data-
sharing model.
GAIN Study Data Sets
The six GAIN studies are presented in
Table 1. Most of these studies include
more than one data set, or group of
participants with distinct DULs on
permissible research (see Table 2 for a
glossary of terms). In conjunction
with their institutional review boards,
the principal investigators (PIs) of
each of the GAIN studies developed
the DULs on the basis of the partici-
pants’ informed consent. These
DULs, such as the GAINmajor-depres-
sion study’s limitation to ‘‘genetic
studies of psychiatric health and
related somatic conditions,’’ might
require interpretation by the DAC.
Although the GAIN PI defined these
terms clearly for the DAC’s use,
knowledge of phenotypes composing
or related to psychiatric disorders is480 The American Journal of Human Geneticssomewhat specialized and makes
essential the inclusion of a DAC
member with psychiatric expertise
(e.g., Thomas Lehner, National Insti-
tute of Mental Health). On numerous
occasions, the PIs of the GAIN studies
joined the DAC meetings via confer-
ence call to provide their perspective
on the appropriate interpretation of
DUL statements. GAIN studies with
more than one data set, such as the
GAIN schizophrenia study, often
involved a ‘‘tiered’’ consent in which
participants could opt to allow their
data and samples to be used for
any genetic studies (i.e., for ‘‘general
research use’’ [GRU]) or limit the use
to genetic studies of schizophrenia
and related conditions (SARCs).
Approved users are able to download
only the dbGaP data sets for which
they are approved—for example, an
investigator approved to access only
the GAIN schizophrenia GRU data
set cannot download data from the
SARC or major-depression data sets.
The GAIN DAC
The GAIN DAC is composed of
eight senior scientists who are from
several NIH institutes and who have
appropriate scientific, bioethics, and
human-subjects research expertise.
Many of the DAC members have pre-
viously served on or chaired institu-
tional review boards and bring this
important perspective to the evalua-
tion of PRs. Because dbGaP was devel-
oped and is maintained by the NIH,
it is considered a federal database
and all members of the DAC must
be federal employees. DAC members
are asked to serve 3 year terms,
although some have been members
since the inception of the committee
in 2007. Before a new member begins
voting on PRs, he or she attends
several committee meetings as an
orientation to the GAIN data sets
and their DULs and the review pro-
cess. For the first few years of its exis-
tence, the GAIN DAC met in person
on a weekly basis to develop opera-
tional procedures and discuss each
submitted PR in great detail.
The GAIN DAC reviews requests
for the ten GAIN data sets housed92, 479–488, April 4, 2013in dbGaP. A PR may include multiple
data-set requests. The GAIN DAC’s
primary charge is to determine
whether the proposed research
described in each PR is consistent
with the DULs for each of the
requested data sets. For example, a
researcher who is submitting a PR for
schizophrenia research and who has
requested the GAIN schizophrenia
data sets (GRU and SARC) and the
diabetic nephropathy in type I dia-
betes (DN) data set would be denied
access to the DN data set because
schizophrenia is not considered a
complication of type I diabetes and
the DN DUL requires that it be.
Figure 1 outlines the process for PR
submission and review. PRs for GAIN
data are submitted online through
dbGaP via the Electronic Research
Administration (eRA) Commons, an
online interface that allows grant
applicants, grantees, federal staff at
NIH, and other federal grantor
agencies access to administrative in-
formation relating to research grants.
Detailed information describing the
process for PR submission and DAC
preliminary review can be found
in the Supplemental Data, available
online.
Once the PR is received and a pre-
liminary review by GAIN DAC staff
is complete, the PR is made available
to the DACmembers through a secure
site and initial voting takes place
electronically. DAC members review
each request for consistency with
the DULs and vote to approve, disap-
prove, or discuss the request at the
next DAC meeting. PRs that receive
unanimous electronic votes for
approval or disapproval do not require
further discussion. PRs without
unanimous approval via electronic
voting are discussed at the DAC
meeting, and a vote to approve or
disapprove the PR is held at the end
of discussion. All new PRs must be
reviewed and voted on by the DAC,
either electronically or in person, to
be approved. PRs submitted for an
additional year of access after the
original access period has expired are
reviewed by the DAC chair and are
only discussed by the entire DAC if
Table 1. GAIN Studies and Data Sets
GAIN Study (dbGaP
Accession Number)
Publication
Embargo Date DULs for GAIN Study Data Set(s)a Sample Size
Number of
Approved PRs
(through 12/31/11)
ADHDb (phs000016) 3/26/08 Limited to genetic studies of the
pathophysiology or etiology of ADHD or
its complications.
2,758 (924 trios) 155
Nephropathy in type I
diabetes (phs000018)
7/9/08 Limited to research on type 1 diabetes and
its complications. Complications include
nephropathy, cardiovascular disease,
retinopathy, neuropathy, and mortality.
Phenotypes related to diabetes and its
complications, such as body mass index,
blood pressure, lipids, and hemoglobin A1C,
may also be studied.
1,825 (904 cases, 881
controls, and 40 others)
107
Major depressive disorder
(phs000020)
7/9/08 Limited to genetic studies of psychiatric
health and related somatic conditions.
Psychiatric health refers to DSM-IV or
ICD-10 psychiatric disorders. ‘‘Related
somatic conditions’’ refers to general medical
disorders whose risks have been elevated in
individuals with psychiatric disorders
(e.g., cardiovascular disease or migraine).
3,741 (1,821 cases, 1,822
controls, and 98 others)
206
Psoriasis (phs000019) 8/13/08 GRU 1,677 (950 cases, 692
controls, and 35 others)
151
Limited to genetic studies of autoimmune
disease.
1,198 (449 cases, 734
controls, and 15 others)
73
Schizophreniac (phs000021) 12/3/08 GRU 4,591 (1,217 EA cases,
1,442 EA controls,
953 AA cases, and
979 AA controls)
421
Limited to genetic studies of schizophrenia
and related conditions, which include those
with evidence of genetic relationships to
schizophrenia or schizoaffective disorder,
such as acute psychoses, bipolar disorder,
major depressive disorder, or ‘‘cluster A’’
personality disorders (schizotypal, schizoid,
and paranoid personality disorders).
475 (187 EA cases
and 288 AA cases)
227
Bipolar disorderd (phs000017) 12/1/08 GRU 1,767 (1,081 EA controls
and 656 AA controls)
286
Bipolar and related disorders. 841 (691 EA cases and
150 AA cases)
216
Bipolar disorder only. 653 (388 EA cases and
265 AA cases)
180
The following abbreviations are used: ADHD, attention-deficit hyperactivity disorder; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition; ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; GRU, general research use; EA, European
American; and AA, African American.
aA data set comprises groups of participants with DULs on permissible research. One or more data set(s) can make up a GAIN study. Multiple data sets may be
requested in each PR.
bThere were 2,835 phenotyped subjects (949 trios) for v.1 and 2,758 phenotyped subjects (924 trios) for v.2.
cThere were 2,846 phenotyped subjects for v.1, 5,066 phenotyped subjects for v.2, and 5,064 phenotyped subjects for v.3.
dThere were 2,160 phenotyped subjects for v. 1, 3,261 phenotyped subjects for v.2, and 3,261 phenotyped subjects for v.3.the scope of the research has changed
since the last approval.
Key Aspects of GAIN Data-Access
Governance
Figure 2 illustrates the governance
structure for the GAIN data-access
process. The GAIN Steering Commit-
tee was responsible for overall
guidance to the project and helpedestablish data-access principles and
policies that the GAIN DAC then
implemented. The Steering Commit-
tee paid particular attention to partic-
ipant protections, both during data
submission from the original studies
and during data access and use by
outside investigators.1 The NIH estab-
lished the Advisory Committee to the
Director (ACD) Working Group onThe American Journal of HumaParticipant and Data Protection
(ACD PDP) to serve as a source of
independent advice about GAIN
participant protection and data-
management policies in order to sup-
port the use of GAIN data in a manner
consistent with participant consent
and robust standards for protecting
participant privacy and confidenti-
ality. The ACD PDP included ethicists,n Genetics 92, 479–488, April 4, 2013 481
Table 2. Glossary of Terms
Term Abbreviation Definition
Annual report AR A report submitted to the DAC on the anniversary of access approval. It summarizes
the analysis of NIH genomic data sets obtained through the PRs and any significant
findings derived from the work.
Approved user AU Post-DAC approval will include the PI, home-institution collaborators who are
named in the ‘‘Senior/Key Person Profile’’ portion of the PR, the IT director or
designee named in the ‘‘Senior/Key Person Profile’’ portion of the PR, and
trainees or staff to these investigators.
Data-management incident DMI Occurs when any of the terms of the NIHDUC agreement have been compromised.
Data set - Group of participants with distinct DULs on permissible research. One ormore data
sets can make up a GAIN study.
Data Use Certification DUC The agreement that outlines the terms of access for NIH genomic data. The DUC
is signed by the PI and signing official upon submission of a PR to the NIH.
Database of Genotypes and Phenotypes dbGaP Currently serves as the primary NIH GWAS data repository.
GAIN study - One of six studies contributed to the NIH GWAS data repository (dbGaP) as part
of the GAIN Consortium activities. Each study focuses on one disease and consists
of one or more data sets.
Institutional signing official SO Someone who has the authority to sign on behalf of the PI’s research institution
and who is credentialed through the eRA system as such.
Information-technology director IT director Someone with the authority to verify the IT data-security capacities at an
institution or a higher-level division of an institution (e.g., the school of medicine).
Participant Protection and Data
Management Steering Committee
PPDM The principal trans-NIH committee within the GWAS governance structure. It is
charged with providing ongoing review and development of specific policies and
procedures related to issues of participant protection in GWAS data submission,
data management, and data distribution and with promoting communication
across the various NIH DACs.
Project request PR A request for dbGaP data sets. It contains the SF 424 (R&R) cover pages and
requested attachments, if any.
Senior Oversight Committee SOC The principal NIH GWAS governance committee that advises the NIH director
on the policies, procedures, and issues regarding the ongoing implementation
and monitoring of the GWAS policy and data-sharing practices for other genomic
data deposited to dbGaP.
The following abbreviations are used: SF 424, standard form 424; and R&R, research and related.scientists, statisticians, and represen-
tatives from the general public (see
Supplemental Data for the ACD PDP
roster). For the first few years of the
GAIN program, the ACD PDP met
semiannually and reported back to
the NIH ACD. Minutes from these
public meetings are available online.
In December 2007, the ACD PDP re-
ported that the policies for data access
and review were robust. They had also
considered the potential scope of
secondary use of data for research
and determined that some uses—for
example, methodological studies—
are acceptable. Additional recommen-
dations from the ACD PDP included
that the NIH should (1) seek a
Freedom of Information Act exemp-
tion #3 provision to provide addi-
tional privacy protections for those
participants whose data are stored in482 The American Journal of Human GeneticsdbGaP and (2) develop a system for
addressing public inquiries about
GWASs and the repository. The NIH
agreed with these recommendations
and, for the latter, took steps to
enhance the website and thematerials
available to improve transparency
and accessibility of the information
within it. In addition to disseminating
materials, the NIH has maintained a
dedicated email address to receive
questions or comments about the
GWAS policy. The ACD PDP
concluded its work in the summer of
2009 because GAIN oversight was
fully integrated into the NIH gover-
nance structure developed through
the NIH GWAS policy. Communica-
tion with the ACD on matters
regarding GAIN (and broader GWAS)
data sharing has continued as appro-
priate through that group’s semian-92, 479–488, April 4, 2013nual meetings. The GWAS-policy-
oversight structure includes multiple
committees, including the NIH Partic-
ipant Protection and Data Manage-
ment Steering Committee (PPDM)
and the NIH GWAS Senior Oversight
Committee (SOC). The PPDM is a
trans-NIH committee charged with
providing ongoing review of specific
policies and procedures related to
issues of participant protection in
data management and data distribu-
tion andwith promoting communica-
tion across the institutes and centers.
The SOC is the principle governance
committee that advises the NIH direc-
tor on the policies, procedures, and
issues regarding the ongoing imple-
mentation and monitoring of the
GWAS policy and data-sharing prac-
tices for other genomic data deposited
in dbGaP.
Figure 1. Overview of the GAIN Data-Access Review Process
After a researcher (requestor) submits a PR via dbGaP, the PR is reviewed and signed by the
signing official at the requestor’s institution. The PR undergoes a preliminary review by
the GAIN DAC staff before being sent to the GAIN DAC for a vote. If the PR is approved,
the requestor (approved user) can access data sets from dbGaP. If the PR is disapproved or a
revision to the PR is requested, the requestor can revise and resubmit the PR to begin the
evaluation process again.Summary of GAIN PRs
PR submission rates and types of
proposed research remained roughly
constant between 2007 and 2011
(Table 3), signifying a continued
interest in GAIN data even though
dozens of new study data sets are
available via dbGaP. Seventy-nine
percent (749/946) of PRs submitted
to the DAC were approved. The 749
PRs approved by the DAC reflect
2,022 approved data-set requests.
The average number of GAIN data
sets requested per PR was three. The
schizophrenia GRU data set was the
most frequently requested of the ten
GAIN data sets. This is not surprising
because it is the largest of the GAIN
data sets (n ¼ 4,591), includes both
white and African American partici-
pants, and does not limit research
use to a set of particular conditions.
Ten percent (78/749) of PRs were
partially approved, meaning that
some of the requested data sets were
determined not to be appropriate for
the research proposed. The majority
of disapproved or partially approval
PRs occurred because the proposed
research did not fit with the DULs
of the requested data sets or, more
frequently, the proposed data uses
were not clearly described. The
remaining PRs were not approved
for reasons such as the requestwas submitted by a graduate student
and not a senior researcher (NIH
policy expects submission by a senior
researcher) or the request alluded to
collaboration with investigators at
another institution but provided
insufficient detail. Sharing data
within such an interinstitution
collaborative group is permissible
if (1) the collaborators and their insti-
tutions are listed in the research-use
statement and (2) each collaborator
submits a separate PR from his or
her own institution and is granted
approval to conduct the research. If
a requester chooses to revise and
resubmit a PR, the PR is reviewed at
the next DAC meeting. Thirty-two
percent (301/946) of PRs were not
sent to the DAC because they either
were missing information and were
disapproved by the DAC chair
or were previously approved and
resubmitted without any modifica-
tions to the proposed research-use
statement for an additional 1 year
access period.
The GAIN DAC aims to review
submitted PRs as quickly as possible.
For the entire 5 year period ending
December 31, 2011, the median
number of days from PI submission
to institutional approval (via the
PIs signing official) was 3 days, and
that from institutional approval toThe American Journal of Humathe DAC’s decision was 12 days.
Since November 2009, the DAC has
met weekly instead of two to three
times per month to accommodate
the steady number of PRs that
continue to be submitted, enabling a
reduction in the median decision
time from 14 days in 2007 and 2008
to 8 days in 2011 (Figure S1).
Requesting investigators came from
a variety of backgrounds and included
both GAIN PIs and their collaborators.
Twenty-five of the 946 submitted
PRs were from GAIN investigators
and collaborators requesting access
to their own data sets. GAIN, unlike
most NIH-funded studies under the
GWAS policy, requires that the orig-
inal GAIN study PIs request their
genotyping data from dbGaP.1 PRs
were also submitted from investiga-
tors from a variety of institutions,
including public nonprofit (12%),
private for-profit (10%), foreign
(25%), and domestic (53%) academic
research institutions. Four hundred
unique PIs from 214 unique institu-
tions requested access to GAIN data
sets. The aims of each PR vary. The
most common proposed research use
was to study GAIN-specific pheno-
types (54% of submitted requests),
and this was followed by method
development (26%) and adding
controls to other studies (17%). No
proposals were received for nonre-
search uses.
Monitoring the Use of GAIN Data
Approved users agree to submit
annual reports summarizing research
progress, publications and presenta-
tions, any problems that arose during
use of the data, and future plans for
using the data (Box 1). Annual reports
are first reviewed by GAIN DAC staff
and then by the DAC chair. Although
94% (708/757) of the annual reports
due to the GAIN DAC as of December
31, 2011, have been submitted and
reviewed, only 39% (274/708) of
reports were submitted on time and
40% were submitted more than
30 days past their due date (data not
shown). As part of an effort to increase
annual reporting compliance, the
GAIN DAC worked with dbGaP, othern Genetics 92, 479–488, April 4, 2013 483
Figure 2. Summary of Key Aspects of Governance for Controlled Access to GAIN Data
Sets through dbGaP
Prior to the implementation of the GWAS policy, both the GAIN Steering Committee and
the Advisory Committee to the Director (ACD) Working Group on Participant and Data
Protection (ACD PDP) provide oversight and input on policy questions related to GAIN
data use, privacy concerns, and other topics, as appropriate. Once the governance struc-
ture for the GWAS policy is operational, oversight of GAIN is integrated with the other
NIH DACs (only 5 of the 13 other DACs are shown here).DAC members, and the PPDM to
develop an automated series of email
reminders to approved users and their
signing officials about pending and
late annual reports. As part of this
new system, if a report is not submit-
ted after these email notifications,
access to dbGaP is suspended until
the report is submitted or the project
is terminated. Furthermore, if an in-
vestigator has an outstanding annualTable 3. GAIN DAC Voting Decisions for Subm
Year
Number of
PRs Submitted PRs to DACa
Ave
Set
2007 75 65 (87%) 1.7
2008 226 176 (78%) 2.9
2009 234 134 (57%) 3.6
2010 196 143 (73%) 3.0
2011 215 127 (59%) 2.9
Total 946 645 (68%) 3.0
aThe total number of PRs that were reviewed by the D
bPartial approvals include those PRs for which at least
cPRs returned for revision are those that were returned
dWithdrawn PRs are those that were withdrawn or rev
484 The American Journal of Human Geneticsreport, he or she will not be approved
for any additional requests for NIH
GWAS data sets until the delinquent
reports are submitted. This new effort
has improved timely submission of
GAIN annual reports in 2012
(compared to 39% in previous years,
52% were submitted on time), and
only 20% were submitted more than
30 days past their due date (it was
40% in previous years).itted PRs through 12/31/2011
rage Data
s per PR Approved Disapproved
Pa
A
5 57 (76%) 16 (21%)
2 190 (84%) 26 (12%)
2 159 (68%) 32 (14%) 23
5 129 (66%) 32 (16%) 26
7 136 (63%) 33 (15%) 1
4 671 (71%) 139 (15%) 7
AC. This does not include PRs that were acted on by
one (but not all) requested data set was approved.
, but not disapproved, because minor changes neede
ised by the PI before the DAC made a decision.
92, 479–488, April 4, 2013Approved users are also asked to
comment on the data-access-request
process and dbGaP system in their
annual reports. Comments from
GAIN approved users are collated
and shared with the PPDM and dbGaP
staff on a regular basis and have led to
improvements in dbGaP. For example,
dbGaP genotype-data files are now
available in a format compatible
with PLINK, a commonly used
genetic-analysis software program,
and PIs can now assign an authorized
downloader from their lab to select,
package, and download files for the
PI and approved project team. Lastly,
the GAIN DAC generates semiannual
reports—which include data-access
and use statistics, summaries of
annual reports submitted, trends in
access requests, and other informa-
tion—for the PPDM and SOC. These
reports enable the NIH to monitor
the data-access system and any issues
that arise from investigator or DAC
perspectives and that might merit
policy or practice updates.
Another key aspect of monitoring
the use of GAIN data involves identi-
fying data-management incidents
(DMIs), compromises of any of the
terms of the NIH Data Use Certifica-
tion (DUC) agreement, as early as
possible and developing systems to
prevent similar DMIs from occurring
again. As part of the DUC agreement,
approved users agree to notify the
GAIN DAC of any unauthorized data
sharing, breaches of data security, or
inadvertent data releases that mightrtially
pprovedb
Returned for
Revisionc Withdrawnd
2 (3%) 0 (0%) 0 (0%)
8 (4%) 1 (0%) 1 (0%)
(10%) 19 (8%) 1 (0%)
(13%) 4 (2%) 5 (3%)
9 (9%) 7 (3%) 20 (10%)
8 (8%) 31 (3%) 27 (3%)
DAC staff alone.
d to be made.
Box 1. Annual Report Elements
d Summary of research progress
d Proposed plans for further research utilizing currently approved NIH GWAS data sets
d List of all completed or accepted scientific presentations that include (or will include) findings generated from
the individual-level NIH GWAS data accessed through dbGaP
d List of manuscripts submitted
d Description of any intellectual property generated as a result of using the NIH GWAS individual-level data
d Summary information on any inappropriate data-release incidents or other data-security issues
d General comments on process and suggestions for improving dbGaP, NIH GWASs, study-specific data access, or
NIH GWAS policy or procedures in generalcompromise data confidentiality
within 24 hr of when the incident is
identified. Furthermore, the regular
review of annual reports enables
GAIN DAC staff to identify potential
DMIs not previously reported by
approved users.
Just over 2% (9/400) of GAIN
approved users have been associated
with eight DMIs. Once a DMI is iden-
tified, the approved user’s signing
official is immediately notified and
the approved user and his or her
research team are informed by the
DAC chair to stop using GAIN data
until the incident can be investigated
and reviewed by appropriate GWAS
governance committees. dbGaP also
temporarily suspends the approved
user’s account to ensure that addi-
tional files cannot be downloaded.
The governance committees involved
in the consideration of DMIs have
varied on the basis of the nature of
the DMI and any existing precedent
for the actions appropriate to manage
any associated concerns or risks to
participants. In each case, the SOC,
the PPDM, or both are informed about
the incident, and in some cases, these
groups meet to deliberate options
for any NIH response within days of
the DMI notification. Table 4 provides
a brief summary of each GAIN
DMI, the corresponding DUC term
impacted, and the preventive mea-
sures implemented at either the
approved user’s institution or the
NIH for ensuring that such inci-
dents did not recur. Preventive
measures include additional data-
security protocols, investigator educa-tion regarding the roles and responsi-
bilities of an approved user, and
dbGaP system checks prior to data
release. Seven of these incidents
occurred in the first few years in
which GAIN data were available
and, in every case, resolution of the
DMI led to improved education of
GAIN approved users and their
colleagues, as well as improvements
to dbGaP and GAIN DAC review
processes.
Discussion
Providing access to large-scale
genomic data sets that include rich
phenotypic information has allowed
hundreds of authorized investigators
to replicate results of their GWASs,
explore new hypotheses regarding
genetic contributions to complex dis-
ease, and develop statistical methods
to analyze large-scale genomics data
sets. For example, the GAIN psoriasis
data sets were used for the develop-
ment of a mathematical model for
immune cell interactions via the
specific dose-dependent cytokine pro-
duction rates of cell populations,7 and
the GAIN schizophrenia data sets
were used for illustrating a new
method for controlling confounding
in case-control studies.8 Additional
findings generated from GAIN data
sets accessed through dbGaP were
presented at the GAIN Analysis II
and GAIN Analysis III workshops
held in 2007 and 2008, respectively.
The PIs of the GAIN psychiatric-disor-
der data sets went on to form the
Psychiatric Genomics Consortium
(PGC) in 2007. The PGC was foundedThe American Journal of Humato integrate and analyze genome-wide
SNP array data for meta- and mega-
analyses and to conduct cross-disor-
der and comorbidity analyses of
GAIN and other data sets. This con-
sortium has since grown to more
than 200 investigators from 19
institutions in 60 countries and
encompasses more than 100,000 par-
ticipants.9 A total of 188 submitted
or published manuscripts have been
reported to the GAIN DAC (115 from
GAIN PIs and co-PIs and 73 from
secondary approved users) as a result
of making just six GAIN studies
available to the broader research com-
munity, and there has been a propor-
tionately small number of DMIs.
This experience demonstrates the
benefits of the GAIN program, which
we believe is indicative of the benefits
to be realized through the NIH GWAS
policy and the NIH controlled-access
system.
Although the GAIN data-access
experience has been positive overall,
recent reports have highlighted the
potential for privacy risks when
genomic and other molecular data
are broadly shared.10–12 Robust
controlled-access data systems and
strict adherence of approved users to
the terms of access can minimize
many of these risks; however, they
do not reduce the risk to zero. It
remains important that research
participants be made aware of rele-
vant privacy risks during the
informed-consent process and be
given ample time to decide whether
to participate in a study.13 Most
importantly, we must continue ton Genetics 92, 479–488, April 4, 2013 485
Table 4. Summary of GAIN DMIs and the Preventive Measures Implemented
DMI Type
Number of
Incidents Brief Summary of the DMI Corresponding DUC Agreement Term Preventative Measures Implemented
Security breach 1 The computer system at an AU’s institution was determined
to be vulnerable. The AU immediately contacted the
institution’s IT department and captured key information
from the affected machines. The GAIN DAC was contacted
a few days after the vulnerability became apparent. After a
thorough analysis by the IT department, there was no
evidence that GAIN data were accessed.
Term 6. Data Security and Data Release Reporting.
The AU agrees to notify the GAIN DAC of any
unauthorized data sharing, breaches of data security,
or inadvertent data releases that might compromise
data confidentiality within 24 hr of when the
incident is identified.
The AU’s institution implemented additional security
measures to protect machines used for analyzing
GAIN data.
Unapproved
research use
2 AUs at two separate institutions submitted annual reports
that described using GAIN data in a manner not described
in the RUS.
Term 1. Research Use. New uses of these data outside
those described in the PR require submission of a new
PR. Modifications to the research project require
submission of an amendment to this application.
At one of these two institutions, a memo in which
dbGaP stressed the importance of the terms of access
for NIH GWAS data was circulated to all investigators.
As of December 2008, AUs have access to GAIN data
for only 1 year instead of 3 years, after which they
must renew their PRs and update the RUS if the
research focus has changed.
Missing IT
director
1 An AU was approved to access GAIN data sets despite the
absence of an IT director on the PR.
Term 1. Research Use.The IT director, someone
with authority to vouch for the IT capacities
at an institution, should be listed as a ‘‘Senior/Key
Person’’ on the PR.
GAIN DAC staff implemented additional checks in the PR
review process, and the NCBI modified the PR system to
make the requirement for an IT director more apparent.
Publication
embargo
violation
1 An abstract was submitted for a scientific meeting prior to
the expiration of the publication embargo date. The GAIN
DAC was notified when the AU called GAIN staff to clarify
how to acknowledge GAIN in presentations. The abstract
was withdrawn and did not appear in the meeting materials.
Term 8. Research Dissemination and Acknowledgment
of NIH GWAS Data Sets. AUs acknowledge the NIH’s
expectation that they will comply with the embargo
date identified in dbGaP and will not present or
publish findings generated from the GAIN data sets
until the embargo date passes.
The AU has since improved education of trainees and staff
associated with research using dbGaP data sets to prevent
any further incidents.
IRB approval 1 An investigator from a GAIN study site was approved to
access a GAIN data set before it was confirmed that he or
she did not have access to personal identifying information
and did not need IRB approval. This was an error on the
part of the DAC staff. The AU’s access to the GAIN data set
was suspended until the IRB memo was received.
Term 2. Institutional and AU Responsibilities.
AUs who might have access to personal identifying
information for research participants in the original
study at their institution or through their
collaborators might be required to have IRB approval.
Multiple checkpoints were implemented in the GAIN DAC
review process. The DUC was updated to clarify when IRB
approval is required for GAIN data sets.
Unapproved
data access
1 The AU was able to access a GAIN data set for which he or
she was not approved. This resulted from an error in how
the files were configured in dbGaP. The NCBI identified the
issue shortly after access was granted, and the AU submitted
a revised PR to include the additional data set.
Term 1. Research Use. Modifications to the research
project require submission of an amendment to
this application.
NCBI staff reviewed the dbGaP system to verify the
configuration files and implemented additional checks
for each data set before it was released to an AU.
Unapproved
data access
1 The AU changed institutions and downloaded a data set to
which he or she was previously granted access. The issue
was identified when the AU contacted the NCBI for help
with the file that was just downloaded.
Term 5. Nontransferability. AUs agree that if they
change institutions during the access period,
they will submit a new PR and DUC in which
the new institution agrees to the NIH GWAS
policy before data access resumes.
When a PI changes institutions, a close-out report is
submitted to verify that data were destroyed at the
original institution. The NCBI developed an automated
system for DACs to close the PR, ensuring that data files
could no longer be accessed. If a PI submits a new
request from a new institution and it is approved,
then files can be accessed again.
The following abbreviations are used: AU, approved user; IT, information technology; RUS, Research Use Statement; and IRB, institutional review board.
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view the controlled-access data-
sharing model as but one approach
to promoting participant privacy
while still enabling advances in
biomedical research to be pursued.
Limitations to the GAIN data-access
process include the complexities
of the request system, difficulty in
receiving annual reports from
approved users in a timely fashion,
relying on annual reports and
approved users to identify potential
data misuses, and a diversity of
approaches that are used for evalu-
ating requests by other NIH DACs
and that can sometimes lead to confu-
sion for investigators requesting data
sets managed by different DACs. If
multiple data sets are requested under
a single PR and some of the respon-
sible DACs request specific revisions,
the revised request must then be rere-
viewed by all the DACs involved.
Modifications to satisfy one DAC
might then run afoul of requirements
by another DAC and so on. To mini-
mize or avoid this, NIH DAC chairs
are meeting regularly through the
PPDM to increase inter-DAC commu-
nication regarding requests that span
multiple DACs and standardize the
PR review process to the extent
possible.
Several improvements have been
suggested or implemented on the
basis of DAC experience and user
comments. For example, as the num-
ber of genomic data sets in dbGaP
continues to grow, the NIH PPDM is
actively working in conjunction with
dbGaP staff to automate and improve
the current PR process to allow inves-
tigators to simultaneously submit
annual reports and access renewal
requests through an online system.
An automated system directly tied to
renewing access to dbGaP data sets
might also increase compliance in
submission of annual reports. In addi-
tion, given the 5 years of data
showing that not a single requesting
investigator or his or her collaborators
have been identified on the sanctions
lists for federal research, the SOC
recently decided that NIH DACs
may discontinue the review of public
websites for determining whether arequesting investigator or his or her
collaborators have been prohibited
from conducting federal research.
This decision was also based on the
fact that the signing officials affirm
that requesting investigators are in
good standing at their institutions.
This procedural change will afford
the DACs more time to focus on other
aspects of the review process. These
changes, along with new services
(developed by dbGaP staff), including
providing genotype-data files in
PLINK format, allowing PIs to assign
an authorized downloader from their
lab to mange file download, simpli-
fying download management for
data sets with thousands of files, sum-
marizing the publication embargo
properties of downloaded data, and
quickly extracting subsets of data
from the extremely large original
genome-sequence submissions, can
make the data-access system more
straightforward and efficient for
investigators, their institutions, and
the NIH DACs while maintaining the
system’s integrity.
GAIN and the NIH GWAS policy
were founded on the principle that
maximum public benefit can be
achieved if innovative research is
pursued through rich and readily
accessible genomic data in a manner
that promotes the utmost respect
and protection for research-partici-
pant interests. The experience of the
GAIN program illustrates that the
data-access process has facilitated
widespread data dissemination,
measured by the nearly 1,000 requests
for data from investigators from
academic, nonprofit, and industry
researchers. There are a growing num-
ber of presentations and publications
from approved users, continued re-
quests for GWAS data, and relatively
few policy violations. Improvements,
such as those described above, are still
needed to enhance efficiency and ease
of use and maintain vigilance in over-
sight practices. The availability of
GAIN data has allowed for numerous
advances in both the understanding
of the genetic underpinnings of
mental-health disorders, diabetes,
and psoriasis and the developmentThe American Journal of Humaand refinement of statistical methods
for identifying genetic and environ-
mental factors related to complex
common diseases.Supplemental Data
Supplemental Data include one
figure, one text box, rosters for key
GAIN governance groups, and a
detailed description of the dbGaP
request system and the GAIN data-
access review process and can be
found with this article online at
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